Regeneron Pharmaceuticals, Inc. (REGN) scored on five pillars from its reported financial statements, and ranked against 212 Healthcare companies.
Regeneron Pharmaceuticals, Inc. (REGN) scores 5.4 out of 10 as of , computed from its reported financial statements. That reads as mixed quality. The reading rests on solvency, and growth is what holds it back.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
We cannot judge Regeneron Pharmaceuticals, Inc. yet, because fewer than five years had both a return on capital and a cost of capital we could measure. This is not a “no”.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
On the filings behind it, Regeneron Pharmaceuticals, Inc. earns 5.4 out of 10 for business quality as of October 19, 2026. That is mixed quality on our scale. A mixed reading means the strengths and weaknesses roughly cancel out, and the case for the business depends on which pillars you care about most. The figure is a weighted average of five pillars, each scored from 0 to 10 against sector-aware benchmarks from reported statements.
Set against 212 Healthcare companies, Regeneron Pharmaceuticals, Inc. lands at the 65th percentile, in the better half of its peers. A typical company in the group scores 4.4, and the best quarter starts from 6.0. Regeneron Pharmaceuticals, Inc. is above that typical reading.
Regeneron Pharmaceuticals, Inc.’s profitability score is 6.5 out of 10 (average). Against a median of 2.7 among 210 Healthcare companies, that is well above the group and the 80th percentile. Profitability in the middle of the range is neither a moat nor a warning: margins and returns look like those of an ordinary business in this line of work.
On solvency, Regeneron Pharmaceuticals, Inc. scores 9.7, a strong reading. Its peers have a median of 6.5 across 150 Healthcare companies, which places it well above them, at the 88th percentile. A high solvency score means leverage is modest relative to earnings and cash flow, which gives management room to act in a bad year.
Regeneron Pharmaceuticals, Inc.’s growth score is 0.7 out of 10 (weak). Against a median of 4.9 among 107 Healthcare companies, that is well below the group and the 4th percentile. A low growth score is common for large, established companies and is not a verdict on quality on its own, but it limits how the business can compound.
On efficiency, Regeneron Pharmaceuticals, Inc. scores 4.5, an average reading. Its peers have a median of 6.0 across 200 Healthcare companies, which places it well below them, at the 27th percentile. Efficiency near the median says the operation is neither unusually lean nor unusually capital hungry.
Regeneron Pharmaceuticals, Inc.’s predictability score is 5.2 out of 10 (average). Against a median of 3.4 among 207 Healthcare companies, that is well above the group and the 70th percentile. An average predictability reading means results have wobbled about as much as is normal for the sector.
This is a lopsided profile. Solvency scores 9.7 but growth only 0.7, a gap of 9.0 points, so the overall hides a business that is excellent in one respect and weak in another. A solvency lead means the balance sheet is the company’s strongest asset, a cushion that buys time when trading gets harder. A growth shortfall often comes with size or a maturing market, and is less of a concern if the other pillars are strong.
Of everything that could lift Regeneron Pharmaceuticals, Inc.’s score, growth matters most. Bringing it up to the 4.9 median of Healthcare companies would take the overall from 5.4 to roughly 6.2. All five pillars could be scored, so the overall uses the full set of weights out of 100: profitability 25, solvency 20, growth 20, efficiency 15, predictability 20.
These are the Healthcare companies closest to Regeneron Pharmaceuticals, Inc. in market value. Each has its own page scored on the same five pillars, so the comparison is like for like.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Regeneron Pharmaceuticals, Inc. scores 5.4 out of 10, which reads as mixed quality. Its strongest pillar is solvency, its weakest is growth. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Regeneron Pharmaceuticals, Inc. ranks at the 65th percentile of the 212 Healthcare companies Lemma publishes a score for. The median there is 4.4 and the top quarter starts at 6.0, against Regeneron Pharmaceuticals, Inc.’s 5.4.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 19, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for REGN are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card